PDS Biotechnology Corporation (PDSB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

PDS Biotechnology Corporation (PDSB) closed at USD 1.41 on 2026-10-14, a change of +51.1 % over the past year, with a market capitalization of USD 94.22M.

PDS Biotechnology Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

PDS Biotechnology Corporation key figures

Previous close

USD 1.41 (2026-10-14)

1-year change

+51.1 %

Market cap

USD 94.22M

Enterprise value

USD 71.53M

P/E ratio (trailing)

-2.50

P/E ratio (forward)

-3.77

EPS (trailing)

-0.52

EPS (forward)

-0.35

PEG ratio

n/a

Price to book

-20.31

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.05

Employees

21

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About PDS Biotechnology Corporation

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for PDS Biotechnology Corporation and compare it with other stocks.